Investors calmer after Oncolytics explains split of Phase III Reolysin trial
This article was originally published in Scrip
Oncolytics Biotech saw its US stock price fall by as much as 25.5% on 12 September when the Canadian developer of oncolytic viruses for the treatment of cancer announced that it would double the number of patients enrolled in its Phase III clinical trial for intravenous Reolysin in combination with carboplatin and paclitaxel for the treatment of head and neck cancers.
You may also be interested in...
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
Flagship Pioneering raised $1.1bn to fund life science companies emerging from Flagship Labs. ARCH, another frequent start-up co-founder, raised two funds totaling $1.46bn to back early-stage biotech.
Aspen Neuroscience, Pandion and iTeos raised $70m, $80m and $125m, respectively. Also, Glide Healthcare closed a €416m ($450m) fund; ElevateBio, Kallyope and SutroVax reveal VC mega-rounds; and Dragonfly adds new funding to its partnering proceeds.